Raynaud’s Syndrome

Top Story

Few rheumatic adverse events from immune checkpoint inhibitors require discontinuation

November 15, 2018
In the Journals

On-demand sildenafil not superior to placebo for Raynaud's syndrome

October 29, 2018
Despite a high probability that on-demand sildenafil is superior to placebo in the treatment of Raynaud’s syndrome, aggregate observed findings failed to…
In the Journals

Wearable devices linked to increased activity in rheumatic diseases

October 11, 2018
The use of wearable devices that track movement is effective in significantly increasing the amount of and time spent performing moderate to vigorous physical activity…
In the Journals

Patients with SSc-related Raynaud's syndrome identify with patterns linked to microangiopathy

September 19, 2018
Patients with Raynaud’s phenomenon related to systemic sclerosis identify with distinct patterns of the disease that may be linked to progression of systemic…
More Headlines »
CME

Multidisciplinary Perspectives in Giant Cell Arteritis: A Team-based Approach for Improved Quality of Care

This activity is supported by an educational grant from Genentech, Inc.

Giant cell arteritis (GCA) is the most common form of medium- and large-vessel vasculitis. If left untreated, patients…
More »
Video
Meeting News

Workplace flexibility significantly impacts employment for patients with RA

November 9, 2018
More »
ABIM MOC CME

AWIR 2nd Annual Immunology Bootcamp Part 3: Signal Transduction and Biosimilars

This activity is supported by educational grants from AbbVie, Inc.; Amgen; Bristol-Myers Squibb; Pfizer, Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.

Chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, psoriatic arthritis, vasculitis, and axial…
More »